Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
公司代碼GRAL
公司名稱Grail Inc
上市日期Jun 12, 2024
CEORagusa (Robert)
員工數量1000
證券類型Ordinary Share
年結日Jun 12
公司地址1525 O'brien Drive
城市MENLO PARK
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編94025
電話18336942553
網址https://grail.com/
公司代碼GRAL
上市日期Jun 12, 2024
CEORagusa (Robert)